Novartis
NVS
Novartis (NVS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.41
- EPS estimate
- $2.17
- EPS surprise
- +10.95%
- Revenue surprise
- +2.43%
- Revenue
- $14.4B
- Revenue estimate
- $14.1B
- Reported
- Jul 21, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 21, 2026 | $2.17 | $2.41 | +10.95% | $14.4B | SEC |
| Q1 2026 | Apr 28, 2026 | $2.10 | $1.99 | −5.13% | $13.1B | SEC |
| Q4 2025 | Feb 4, 2026 | $1.98 | $2.03 | +2.38% | $13.3B | SEC |
| Q3 2025 | Oct 28, 2025 | $2.27 | $2.25 | −1.00% | $13.9B | SEC |
| Q2 2025 | Jul 17, 2025 | $2.35 | $2.42 | +2.94% | $14.1B | SEC |
| Q1 2025 | Apr 29, 2025 | $2.11 | $2.28 | +7.86% | $13.2B | SEC |
| Q4 2024 | Jan 31, 2025 | $1.80 | $1.98 | +9.73% | $13.2B | SEC |
| Q3 2024 | Oct 29, 2024 | $1.94 | $2.06 | +6.27% | $12.8B | SEC |
| Q2 2024 | Jul 18, 2024 | $1.85 | $1.97 | +6.46% | $12.5B | SEC |
| Q1 2024 | Apr 23, 2024 | $1.68 | $1.80 | +7.29% | $11.8B | SEC |
| Q4 2023 | Jan 31, 2024 | $1.65 | $1.53 | −7.31% | $11.4B | SEC |
| Q3 2023 | Oct 24, 2023 | $1.67 | $1.74 | +4.37% | $11.8B | SEC |
| Q2 2023 | Jul 18, 2023 | $1.64 | $1.73 | +5.81% | $13.6B | SEC |
| Q1 2023 | Apr 25, 2023 | $1.45 | $1.62 | +11.61% | $13.0B | SEC |
| Q4 2022 | Feb 1, 2023 | $1.35 | $1.44 | +7.01% | $12.7B | SEC |
| Q3 2022 | Oct 25, 2022 | $1.47 | $1.50 | +1.89% | $12.5B | — |
| Q2 2022 | Jul 19, 2022 | $1.43 | $1.48 | +3.62% | $12.8B | — |
| Q1 2022 | Apr 26, 2022 | $1.38 | $1.38 | +0.51% | $12.5B | — |
| Q4 2021 | Feb 2, 2022 | $1.34 | $1.33 | −1.29% | $13.2B | — |
| Q3 2021 | Oct 26, 2021 | $1.55 | $1.62 | +4.51% | $13.0B | — |
Quarterly revenue
Frequently asked questions
When did Novartis (NVS) last report earnings?
Novartis last reported on Jul 21, 2026, covering fiscal Q2 2026.
Did NVS beat earnings estimates?
Yes. Novartis reported EPS of $2.41 for Q2 2026 against a $2.17 estimate — a 10.95% beat.
How much revenue did NVS report last quarter?
Novartis reported $14.4B in revenue for Q2 2026, against a consensus estimate of $14.1B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.